Your browser doesn't support javascript.
loading
DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
Vekariya, Umeshkumar; Toma, Monika; Nieborowska-Skorska, Margaret; Le, Bac Viet; Caron, Marie-Christine; Kukuyan, Anna-Mariya; Sullivan-Reed, Katherine; Podszywalow-Bartnicka, Paulina; Chitrala, Kumaraswamy N; Atkins, Jessica; Drzewiecka, Malgorzata; Feng, Wanjuan; Chan, Joe; Chatla, Srinivas; Golovine, Konstantin; Jelinek, Jaroslav; Sliwinski, Tomasz; Ghosh, Jayashri; Matlawska-Wasowska, Ksenia; Chandramouly, Gurushankar; Nejati, Reza; Wasik, Mariusz; Sykes, Stephen M; Piwocka, Katarzyna; Hadzijusufovic, Emir; Valent, Peter; Pomerantz, Richard T; Morton, George; Childers, Wayne; Zhao, Huaqing; Paietta, Elisabeth M; Levine, Ross L; Tallman, Martin S; Fernandez, Hugo F; Litzow, Mark R; Gupta, Gaorav P; Masson, Jean-Yves; Skorski, Tomasz.
Afiliación
  • Vekariya U; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Toma M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Nieborowska-Skorska M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Le BV; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Caron MC; CHU de Québec Research Centre (Oncology Division) and Laval University Cancer Research Center, Québec City, QC, Canada.
  • Kukuyan AM; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Sullivan-Reed K; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Podszywalow-Bartnicka P; Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland.
  • Chitrala KN; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Atkins J; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Drzewiecka M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Feng W; Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
  • Chan J; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Chatla S; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Golovine K; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Jelinek J; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Sliwinski T; Coriell Institute for Medical Research, Camden, NJ.
  • Ghosh J; Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
  • Matlawska-Wasowska K; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Chandramouly G; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL.
  • Nejati R; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
  • Wasik M; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA.
  • Sykes SM; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA.
  • Piwocka K; Division of Hematology/Oncology, Department of Pediatrics, Washington University at St. Louis, St. Louis, MO.
  • Hadzijusufovic E; Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland.
  • Valent P; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Pomerantz RT; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
  • Morton G; Department for Companion Animals & Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria.
  • Childers W; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Zhao H; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
  • Paietta EM; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
  • Levine RL; Moulder Center for Drug Discovery, Temple University School of Pharmacy, Philadelphia, PA.
  • Tallman MS; Moulder Center for Drug Discovery, Temple University School of Pharmacy, Philadelphia, PA.
  • Fernandez HF; Department of Clinical Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
  • Litzow MR; Department of Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY.
  • Gupta GP; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Masson JY; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Skorski T; Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, FL.
Blood ; 141(19): 2372-2389, 2023 05 11.
Article en En | MEDLINE | ID: mdl-36580665
Leukemia cells accumulate DNA damage, but altered DNA repair mechanisms protect them from apoptosis. We showed here that formaldehyde generated by serine/1-carbon cycle metabolism contributed to the accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells, especially in driver clones harboring oncogenic tyrosine kinases (OTKs: FLT3(internal tandem duplication [ITD]), JAK2(V617F), BCR-ABL1). To counteract this effect, OTKs enhanced the expression of DNA polymerase theta (POLθ) via ERK1/2 serine/threonine kinase-dependent inhibition of c-CBL E3 ligase-mediated ubiquitination of POLθ and its proteasomal degradation. Overexpression of POLθ in OTK-positive cells resulted in the efficient repair of DPC-containing DNA double-strand breaks by POLθ-mediated end-joining. The transforming activities of OTKs and other leukemia-inducing oncogenes, especially of those causing the inhibition of BRCA1/2-mediated homologous recombination with and without concomitant inhibition of DNA-PK-dependent nonhomologous end-joining, was abrogated in Polq-/- murine bone marrow cells. Genetic and pharmacological targeting of POLθ polymerase and helicase activities revealed that both activities are promising targets in leukemia cells. Moreover, OTK inhibitors or DPC-inducing drug etoposide enhanced the antileukemia effect of POLθ inhibitor in vitro and in vivo. In conclusion, we demonstrated that POLθ plays an essential role in protecting leukemia cells from metabolically induced toxic DNA lesions triggered by formaldehyde, and it can be targeted to achieve a therapeutic effect.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Daño del ADN / Leucemia / Proteína BRCA1 Límite: Animals Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Daño del ADN / Leucemia / Proteína BRCA1 Límite: Animals Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article